U.S. markets close in 4 hours 45 minutes

Exact Sciences Corporation (EXAS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
101.68-1.11 (-1.08%)
As of 11:15AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
Previous Close102.79
Open102.34
Bid101.85 x 800
Ask102.06 x 1300
Day's Range101.38 - 103.16
52 Week Range70.75 - 159.54
Volume195,944
Avg. Volume1,298,420
Market Cap17.484B
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-5.27
Earnings DateOct 25, 2021 - Oct 29, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est148.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Exact Sciences Corporation
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
    Rating
    Fair Value
    Economic Moat
    25 days agoMorningstar
View more
  • MarketWatch

    Exact stock surges as changes to Pfizer's sales agreement a 'positive,' analyst says

    Shares of Exact Sciences Corp. rallied 8.0% in afternoon trading Wednesday, after the molecular diagnostics company said it taking over the selling of its Cologuard at-home colon cancer screening test from Pfizer Inc. , and said it was discussing with Pfizer "material changes" to their promotion agreement. The company said it learned in late August that Pfizer cut the sales positions supporting its business tasked with selling Cologuard, so Exact offered those displaced sales representatives job

  • Motley Fool

    3 Crash-Ready Stocks to Buy in September

    To find stocks that fit the description, we asked three Motley Fool contributors to share which stock they thought could help investors stay calm amid any market turbulence. Jason Hawthorne (Exact Sciences): Since 2014, Exact Sciences has been known for Cologuard, its at-home test for early cancer screening.

  • Insider Monkey

    10 Best Stocks to Buy for the Next Ten Years

    In this article, we will examine the reasons why Cathie Wood is sticking to her innovation-centric strategy despite lower than expected performance in the first half of 2021. We will also review the 10 best stocks to buy for the next ten years based on Cathie Wood’s Q2 portfolio. You can skip our detailed discussion […]